日本梅毒疫情形势严峻。12020年日本梅毒病例约为6000人，到2025年已超过13000人，感染人数翻倍增长。1与此同时，治疗梅毒的首选药物青霉素制剂供应陷入严重短缺，为患者及公共卫生构成威胁。1
主要供应商辉瑽公司面临生产困难。1该公司治疗药物在2025年7月因异物混入被召回，11月又发生生产设备故障，导致药物供应中断。1根据预计，辉瑽需要到2026年下半年才能恢复出货。1
这一延迟尤其令人担忧。青霉素不仅是治疗梅毒的首选药物，也是阻断梅毒在母婴间传播的唯一推荐药物。1孕妇感染梅毒可导致先天性梅毒。1学会在8月公布见解，要求优先保障孕妇及难以使用替代性药物的患者的用药需求。1
Japan is facing a dual health crisis as syphilis infections continue to climb while supplies of the primary treatment medication dry up. The number of confirmed syphilis cases has more than doubled over the past five years, rising from approximately 6,000 in 2020 to over 13,000 in 2025.1 This surge coincides with a critical shortage of penicillin-based medications, the first-line treatment for the infection.
The drug supply crisis stems from production disruptions at manufacturer Meiji Seika Pharma. The company's treatment product was recalled in July 2025 due to foreign material contamination, followed by a production equipment malfunction in November.1 As a result, the company does not expect to resume shipments until the second half of 2026.1 The shortage carries particular urgency for pregnant women, as penicillin remains the only recommended medication for preventing mother-to-child transmission of syphilis.1 In response to the crisis, a medical society released guidance in August calling for prioritized allocation of available penicillin supplies to pregnant women and patients unable to use alternative medications.1
评论
还没有评论，欢迎留下第一条。